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Retrospective Evaluation of Admissions for Chemotherapy-Induced 
Nausea, Vomiting, and Dehydration
Katelin Van Leer, PharmD; Janine Barnaby, RPh, BCOP
This study will retrospectively review chemotherapy patients for admissions due to 
dehydration, nausea, and vomiting to evaluate Lehigh Valley Health Network’s (LVHN) 
protocol for prevention of such admissions and emergency room (ER) visits. 
This study is fundamentally descriptive.  Rates of admission for chemotherapy-induced 
nausea and vomiting appear to be increasing at LVHN without a known cause.  We 
anticipate a pattern of admissions to emerge which will be able to be used to guide an 
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Background
•  Today, many of our patients do not experience vomiting while undergoing 
chemotherapy due to improved prophylaxis regimens and agents, but it is certainly still 
a problem.1  The risk of chemotherapy-induced nausea and vomiting (CINV) lasts for 
at least 3 days after a high risk and 2 days after a moderate risk regimen’s last dose of 
chemotherapy.3   
•  Patient characteristics that increase risk for CINV include young age, female gender, 
previous chemotherapy experience, previous CINV, gastrointestinal obstruction, and 
metastases, among many factors.2,4,5 
•  Chemotherapeutic agents are classified into categories based on their potential to 
induce nausea and vomiting, as illustrated in Figure 1.2,5 
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•  The primary outcome of this study will be rates of admissions (number of 
chemotherapy admissions/number of chemotherapy administrations) compared by 
chemotherapeutic medication and by care plan emetogenicity.
   −  Care plan emetogenicity is predefined at LVHN based on regimen medications.
•  Secondary outcomes will be admission rates compared by prophylactic antiemetic 
and by hydration method, as well as length of stay compared by care plan 
emetogenicity level. 
•  Patient data to be collected includes: 
     −  Age, gender, weight
   −  Presence of metastases, site of cancer, completed cycles of chemotherapy, history 
of CINV
   −  Chemotherapy prescribing physician, location of chemotherapy treatment, 
chemotherapy medications and doses, regimen emetogenicity (as previously 
defined in the LVHN standardized care plan), pre-chemotherapy antiemetic and 
hydration, pre-chemotherapy antiemetic timing with regard to administration of 
chemotherapy (appropriate or inappropriate, where appropriate is defined as 
administration 30 to 60 minutes prior to chemotherapy administration), compliance 
with prophylactic antiemetic
•  Current antiemetic therapy is varied and often involves 
a combination of antiemetics to control CINV. Therapy 
can include medications as illustrated in Figure 2.2 
Retrospective chart review of admissions for nausea, vomiting, or dehydration in 
patients receiving any IV chemotherapy including ER admissions, ER discharges, and 
direct admissions over 1 year
Study Design
Study Population
•  Inclusion Criteria:  
   −  Patients undergoing intravenous chemotherapy in the outpatient chemotherapy 
centers at LVHN
   −  Patients with an ER visit to admission, ER visit to discharge, or direct hospital 
admission for nausea, vomiting, or dehydration within 10 days after receiving IV 
chemotherapy
•  Exclusion Criteria:  
   −  Patients admitted for a reason other than nausea, vomiting, or dehydration
   −  Patients with repeat admissions for nausea, vomiting, or dehydration on the same 
chemotherapy regimen
   −  Patients receiving oral chemotherapy
Statistical Analysis
•  Primary outcomes will be reported as rate of admission for each emetogenicity level 
and each predefined care plan. 
•  Two-sided 95% confidence intervals will be computed around the admission rates.  
These confidence intervals will describe the range of underlying probabilities of 
admission for CINV that are potentially consistent with the observed admission rates.
•  Admission rates will be modeled with logistic regression to assess the relationship 
between the likelihood of admission for CINV and the levels of the various covariates 
that will be collected.
•  The choice of antiemetic should be based on the emetic 
risk of therapy, prior antiemetic experience, and other 
patient factors.5 
•  In a review of single-dose chemotherapy, CINV events 
did differ by emetogenicity of the regimen.6  
   −  Rates of CINV with first administration of chemotherapy 
ranged from 4.4% with low emetogenic chemotherapy 
to 13.8% with highly emetogenic chemotherapy, 
and have been shown to increase with subsequent 
chemotherapy administrations.4 
   −  Breakthrough nausea and vomiting overall has been 
studied to be approximately 30-40% with highly 
emetogenic regimens and 15-30% with moderately emetogenic regimens, so there is 
still a need to reduce CINV further with improved prophylaxis.
•  Currently at LVHN, traditional antiemetic care is given as indicated in the National 
Comprehensive Cancer Network (NCCN) guidelines, however, these guidelines are 
very broad and may not be capturing all patients that require improved antiemetic 
therapy.  
   −  Days between last chemotherapy dose and admission, admit reason (nausea, 
vomiting, dehydration), admit method (direct admission, ER to admit, or ER to 
discharge), day of week presenting to ER or hospital for CINV, hydration fluids, and 
antiemetic therapy upon admission
     •  Admissions within 10 days of the last chemotherapy dose will be attributed to 
chemotherapy. 
     •  If the patient changes chemotherapeutic regimen or dosing, another admission will 
qualify as another documentable incidence of CINV admission due to the change. 
•  Through this study, we hope to evaluate the incidence of CINV in our chemotherapy 
patients in order to modify prophylactic treatment to reduce admissions for CINV and 
improve patient tolerance of chemotherapy.
Emetic risk of 90% or moreHigh emetogenic chemotherapy (HEC)
Emetic risk of 30 to 90%Moderate emetogenic chemotherapy (MEC)
Emetic risk of 10-30%Low emetogenic chemotherapy (LEC)
Emetic risk less than 10%Minimal emetogenic chemotherapy
Figure 2. Common Chemotherapy Antiemetics
Figure 1. Emetogenicity Levels of Chemotherapy
